OBR moved to London in late 2011 with the first annual “Courage in Innovation” award being presented to Dr Lerner and Sir Gregory Winter at Imperial College London. King’s College London, University College London and Queen Mary, University of London joined soon thereafter, with all four universities hosting OBR events in 2012. OBR has since established ties with the London Research Institute, Institute of Cancer Research, Royal Veterinary College and MRC National Institute for Medical Research. We look forward to expanding to the many world-class institutions still remaining in London and forging close ties with the many exciting firms in the London biotech cluster and the City. Please contact Sybil Wong for enquiries regarding academic or industry partnerships and joining the OBR-London team.
Sybil is a final year PhD student in Biochemistry jointly affiliated to Barts Cancer Institute, Queen Mary, University of London, and the University of Nottingham. She is currently dissecting the molecular mechanisms underlying microRNA-mediated gene regulation. Outside of the lab as a STEM ambassador, she encourages hard-to-reach students to consider careers in science, thus she identifies with OBR's mission to facilitate young scientists to pursue their own ideas.
Shirley holds a joint honours degree in Genetics and Microbiology, and an MSc in Immunology of Infectious Diseases. She is currently a third year PhD student in Microbiology and Immunology at the Dental Institute, King’s College London. Her work focuses on host-microbial interactions at mucosal surfaces, with emphasis on fungal pathogenesis and epithelial signalling. Outside of the lab, Shirley is interested in the latest technological innovations and their applications in biotechnology. As Events Lead of OBR-London, Shirley is looking forward to connecting scientific academia with industry, and encouraging bio-entrepreneurship.
Graham is a Masters student at King’s College London, where he is studying Translational Cancer Medicine. His research focuses on investigating the DNA damage response pathway in breast cancer as a biomarker for therapy response. Having spent two summers working in industry in San Francisco, Graham has developed a strong interest in the biotech and pharmaceutical sectors, with a particular focus on emerging markets. He graduated from Trinity College Dublin in 2013 with a degree in Genetics.
Cinta Abell is a final year MSc Drug Discovery & Pharma Management student at UCL and holds undergraduate degrees in Pharmaceutical Sciences and Organizational Psychology. Cinta’s passion for entrepreneurship has led her to open multiple Bed & Breakfasts and other start-up companies but her main interest lies in pharmaceutical entrepreneurship and building a bio- or pharma-related business. Cinta strongly identifies with OBR’s mission to gap the bridge between academia and industry in order to move ideas forward and foster entrepreneurship among young scientists.
Joanna is a postdoctoral fellow at Cancer Research UK, where her current work focuses on understanding molecular mechanisms of DNA repair pathways associated with cancer. She obtained her PhD in Biochemistry at the Technische Universität München, where she studied molecular chaperones and regulatory role of posttranslational modifications. In addition to her academic research, she is interested in business consulting.
Qize Ding is a 3rd year PhD student at Imperial College London. His research is on the high-throughput screening and isolation of apoptosis inducers against certain mutations in tumour transformation scenarios. He obtained a BSc in Biochemistry and a Masters in Immunology at Imperial College London. He is has a strong interest in the business consulting for the biotechnology and pharmaceutical industries.
Francesca is a post-doctoral research associate at the MRC Centre for Developmental Neurobiology at King’s College London. Her research focuses on understanding the mechanisms that underlie the specification of different brain areas using various experimental models. She interested in science communication and especially in promoting a dialogue between science and society.
Maria Jose Martin
Maria Jose is a Marie Curie postdoctoral fellow at Clare Hall (Cancer Research UK). She has always been interested in understanding and visualising the molecular machines that repair our DNA. During her PhD at the Molecular Biology Centre in Madrid, she worked with polymerases involved in a major pathway of DNA repair, both in humans and in pathogenic bacteria. In her current research, she is studying human enzymes involved in homologous recombination and cancer. Maria Jose believes in the importance of translational science, to transform the knowledge created in labs into applications for the real world.
Simcha is an Assistant Professor (Lecturer) in Management Science and Innovation at University College London. He is a principal investigator on a number of research projects that focus on enhancing our understanding of the innovative and competitive dynamics governing new science-based industries in fields such as biotechnology. Simcha’s work has been published in international management journals such as Industrial and Corporate Change and Research Policy as well as practitioner oriented publications such as Nature Biotechnology. Simcha was elected Honorary Cambridge University European Trust Scholar and was awarded several grants and awards for his research including the first prize in the PRIME Early Career Competition and a DIME WP European Framework Grant for qualitative research on university entrepreneurship.
One Nucleus was formed in April 2010 by the merger of two regional lifescience networks – Cambridge-based ERBI and the London Biotechnology Network (LBN). Together we form a commercial, clinical and academic powerhouse. London and Cambridge are home to at least 60% of the UK’s life science industry base, four of the UK’s five Academic Health Science Centres and three of the world’s top six universities. The merger of ERBI and LBN recognises that the Cambridge-London network is an international life science “super cluster”. One Nucleus is a membership organisation for international life science and healthcare companies. We are based in Cambridge and London UK, the heart of Europe’s largest life science and healthcare cluster. Our vision for us and our members is to be the top European life science and healthcare network. And our mission is to achieve this by maximising the global competitiveness of our members. More than 500 members include pharmaceutical, biotech, medical device and diagnostic companies and associated technical and commercial service providers.
Barts and The London School of Medicine and Dentistry, part of Queen Mary University of London, offers international levels of excellence in research and teaching while serving a population of unrivalled diversity. Through partnership with our linked trusts, notably Barts Health NHS Trust, and our associated University Hospital Trusts – Homerton, Newham, Whipps Cross and Queen’s (Romford) the School’s research and teaching is informed by an exceptionally wide ranging and stimulating clinical environment. Its fundamental mission, with its partner NHS Trusts, and other partner organisations, such as CR-UK, is to ensure that that the best possible clinical service is underpinned by the very latest developments in scientific and clinical teaching, training and research. http://www.smd.qmul.ac.uk/
Tommaso is a third year PhD student at Imperial College working on cardiovascular regenerative medicine. He is investigating the beneficial effects of a therapeutical-like approach during the onset of cardiac hypertrophy using a cell delivery system in vivo. This work involves the use of molecular biology, cell culture and cardiac surgery techniques.
Francesco is a medical doctor now PhD student at NHLI Imperial College London. His project aims at implementing a translational genomics approach to dissect mechanisms of heart failure and recovery integrating high-throughput -omics data. He is interested in technology transfer with main focus on patents and start-ups